Page 2 - Herriot Tabuteau News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Herriot tabuteau. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Herriot Tabuteau Today - Breaking & Trending Today

Phase 3 Trial of AXS-12 for Narcolepsy Meets Primary Endpoint

The treatment significantly reduced the frequency of cataplexy attacks in patients with narcolepsy compared with placebo. ....

Herriot Tabuteau , Michael Thorpy , Wake Disorders Center , Albert Einstein College Of Medicine , Montefiore Medical Center , Orphan Drug Designation , Sleep Wake Disorders Center , Albert Einstein College , Axsome Therapeutics , Accessed March ,

Axsome Therapeutics : AXS-12 SYMPHONY Results - Slides -March 25, 2024 at 08:33 am EDT

Topline data

March 25, 2024

Forward Looking Statements & Safe Harbor

Certain information contained in this. ....

United Kingdom , Herriot Tabuteau , Mark Jacobson , Cooherriot Tabuteau , Michaelj Thorpy , Thorpy Axsome , Changeinweekly Cataplexyattacks , Cambridge University Press , Axsome Therapeutics Inc , Drug Administration , Cambridge University , Private Securities Litigation Reform Act , Axsome Therapeutics , Narcolepsy Summary , Cognitive Function , Pharmacol Exp , Epworth Sleepiness Scale , Narcolepsy Symptom Assessment Questionnaire , Excessive Daytime Sleepiness , Clinical Global , Weekly Cataplexy ,

Axsome Therapeutics Announces New SYMPHONY, CRESCENDO Data in Narcolepsy

The SYMPHONY trial found reboxetine can significantly reduce cataplexy, excessive daytime sleepiness, cognitive impairment, depression, and anxiety for patients with narcolepsy. ....

Herriot Tabuteau , Michael Thorpy , Wake Disorders Center , Montefiore Medical Center , Drug Administration , Sleep Wake Disorders Center , Albert Einstein College , Epworth Sleepiness Scale , Epworth Sleepiness , Orphan Drug Designation , Axsome Therapeutics ,

AXS-12 Reduces Narcolepsy Symptoms in Phase 3 Trial

Axsome Therapeutics announced topline trial results, which show AXS-12 significantly improves key narcolepsy symptoms. ....

Michael Thorpy , Herriot Tabuteau , Albert Einstein College Of Medicine , Montefiore Medical Center , Wake Disorders Center , Axsome Therapeutics , Axsome Therapeutic , Clinician Global Impression , Narcolepsy Symptom Assessment , Epworth Sleepiness Scale , Cognitive Function Items , Functional Outcomes , Sleep Questionnaire , Sleep Wake Disorders Center , Albert Einstein College ,

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call Transcript February 20, 2024 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-2.08 EPS, expectations were $-1.21. Axsome Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and […] ....

Mark Jacobson , Total Sunosi , Axsome Therapeutics , Axsome Therapeutics , Fourth Quarter , Nick Pizzie , Ari Maizel , Clinical Trials , Herriot Tabuteau ,